NCT00053573View on ClinicalTrials.gov

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

November 30, 2006

Conditions
Glycogen Storage Disease Type IIPompe DiseaseAcid Maltase Deficiency DiseaseGlycogenosis 2
Interventions
BIOLOGICAL

Myozyme

20 mg/kg to 40 mg/kg qow

Trial Locations (6)

27710

Duke University Medical Center, Durham

31096

Rambam Medical Center, Haifa

32610

University of Florida College of Medicine, Gainesville

45229

Children's Hospital Medical Center, Cincinnati

Unknown

Pediatrique Hopital de Brousse, Lyon

M27 4 HA

Royal Manchester Children's Hospital, Manchester

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00053573 - rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease) | Biotech Hunter | Biotech Hunter